Joel Jernigan

ntic for species managed under the Fishery Management Plan for the Snapper-Grouper Fishery of the South Atlantic Region. This restriction would remain in place until the completion of the South Atlantic Great Red Snapper Count study and the integration of the data from that study into the stock assessment.

The purpose of this bill is to ensure that any decisions regarding area or bottom closures in the South Atlantic are based on the most up-to-date and accurate information available. By waiting for the completion of the Great Red Snapper Count study and incorporating its findings into the stock assessment, policymakers can make more informed decisions that will benefit both the fishery and the environment.

This legislation is important for the sustainable management of the Snapper-Grouper Fishery in the South Atlantic region. By delaying any new rules or amendments until the completion of the study, Congress is taking a proactive approach to ensure the long-term health and viability of the fishery. It demonstrates a commitment to evidence-based decision-making and responsible stewardship of our natural resources. Overall, Bill 119 hr 470 represents a thoughtful and non-partisan effort to protect the South Atlantic fishery and promote sustainable practices. It highlights the importance of scientific research and data-driven policymaking in the management of our nation's fisheries.

no clinically meaningful differences from, existing FDA-approved biologic medications.

The bill seeks to increase competition in the biologics market by streamlining the approval process for biosimilars and reducing barriers to entry for manufacturers. This would help lower costs for patients and increase access to life-saving medications.

Key provisions of the bill include: 1. Allowing biosimilar manufacturers to rely on FDA-approved reference products for certain data, reducing the time and cost of development. 2. Establishing a pathway for interchangeable biosimilars, which can be substituted for the reference product without the intervention of a healthcare provider. 3. Providing incentives for healthcare providers to prescribe biosimilars, such as reimbursement incentives and education programs. 4. Improving transparency and communication between the FDA, manufacturers, and healthcare providers to ensure the safety and efficacy of biosimilars. Overall, the Increasing Access to Biosimilars Act of 2023 aims to promote competition, lower costs, and increase access to biosimilar medications for patients in the United States.